N-terminal pro-B type natriuretic peptide (NT-proBNP) were found to be elevated in the circulation of patients with cardiovascular diseases (CVD), including myocardial infarction and HF. 5, 6 BNP is mainly synthesized and secreted by ventricular cardiomyocytes. In human plasma, it consists of 32 amino acids and has various biological activities such as relaxing blood vessels and diuresis. NT-proBNP does not have any known biological activity and is more stable than BNP. 6 The elevated level of BNP and NT-proBNP has been one of the diagnostic criteria of HFpEF and HFmrEF. 1, 7 They have been recommended as first-line biomarkers for the diagnosis of acute and chronic HF and can also be used to rule out acute dyspnea not due to HF and to assess prognosis. [8] [9] [10] At present, there are differences in measurement systems and methods for detecting BNP and NT-proBNP in clinical laboratories around the world. 11, 12 It is worthwhile paying more attention to the accuracy of measurement for BNP and NT-proBNP in all laboratories, as it can directly affect the patient's diagnosis and treatment.
Internal quality control (IQC) is regarded as an effective tool to discover errors and plays an important role in improving the precision level of clinical laboratories and ensuring accuracy and reliability of test results. 13 The coefficient of variation (CV) is an indicator that describes the degree of data variation and is calculated as the standard deviation divided by the mean value multiplied by 100. Derived from IQC data, CV can be used to monitor the imprecision of measurement and reflect the quality of laboratory analysis phase. 14 
| MATERIAL S AND ME THODS

| Subjects
Clinical laboratories in various provinces in China, which continuously participated in an external quality assessment (EQA) program for BNP and NT-proBNP from 2014 to 2017. EQA program is officially organized by the National Center for Clinical Laboratories (NCCL) in China.
| Methods
The IQC information for BNP and NT-proBNP of participant laboratories were collected annually in each April from 2014 to 2017 through Percentages of laboratories meeting the quality requirements for BNP and NT-proBNP were calculated by quality specifications based on biological variation and total error allowance (TEa) provided by evaluation criteria for EQA in laboratory medicine in China. If the current CVs were lower than an evaluation criterion, the precision of the laboratory was considered acceptable under the quality requirements of the standard. The pass rates of each group, which were divided and analyzed by year, measurement systems, etc., defined as the ratio of "number of laboratories with acceptable performance" to "the total number of laboratories of each group."
| Analytical quality specifications
This study used allowable imprecision quality specifications derived from biological variation and TEa recommended by evaluation criteria for EQA in laboratory medicine in China. There were three levels of quality specifications based on biological variation: minimum, desirable, and optimum performances, which were respectively calculated and defined as 0.75CV l , 0.50CV l , and 0.25CV l . CV l , the dence, the value is usually 1.65). 16 The evaluation criteria for EQA of two analytes in China are given as TEa, so the NCCL set the criteria of TEa for these two analytes (both were 30%). Accordingly, the 1/3TEa and 1/4TEa can be calculated for them: 1/3TEa for BNP and NT-proBNP was 10% and 1/4TEa was 7.5%.
| Statistical analysis
The distribution of current CVs was represented by the 25th, 50th
(median), and 75th percentiles. For each analyte, Friedman M test was used to compare current CVs among different years (multiple comparisons between groups using Bonferroni's method Washington, DC, USA). The differences were considered to be statistically significant when the value of P < 0.05.
| RE SULTS
In average. Laboratories which adopted two levels of control materials were 18.36% and 36.50%, respectively. Unfortunately, laboratories which measured three levels were approximately 10% or less. Detailed results are shown in Table 1 . As most laboratories only submitted IQC data for one level of control materials, and most of them tested level 1, the following analysis of current CVs was performed for level 1.
| Imprecision analysis
From 2014 to 2017, the distribution of current CVs for BNP and NTproBNP is shown in Figure 1 . For these two analytes, there were significant differences in current CVs among 4 years (both P < 0.001).
Further analysis of the current CVs of BNP between any 2 years showed that significant differences existed between 2014 and 2017, 2015, and 2017 (both P < 0.001). For NT-proBNP, significant differences in current CVs were between following 2 years: 2014 82.6%-94.0% for NT-proBNP, P < 0.001). Compared with BNP, NTproBNP had higher pass rates regardless of whether 1/3TEa or 1/4TEa was used in 2016 (χ 2 = 11.773 and 10.472, respectively, both P = 0.001). In addition, when applying the desirable and optimum allowable imprecision specifications based on biological variation, the pass rates for NT-proBNP were lower than that using 1/3TEa or 1/4TEa criterion, but it still increased gradually from 2014 to 2017
(55.98%-74.76% for desirable, 10.87%-22.83% for optimum).
| Imprecision analysis by measurement systems
The instruments, reagents, and calibrators used in one laboratory were all purchased from one manufacturer. For all participant laboratories in China, measurement methods for these two analytes were immunoassays. After investigating which measurement systems laboratories used, we found that the main measurement systems for BNP were Abbott, Siemens and Beckman, and for NT-proBNP Table S1 in supplementary materials). From 2014 to 2017, there was no significant change in the constituent ratio of the main measurement systems for two analytes (both P > 0.05). For BNP, the most popular measurement system was Abbott (about 50%), followed by Siemens (about 25%), and Beckman (about 18%). For NT-proBNP, Roche owned the largest constituent ratio (about 80%), followed by J&J (about 6%), Radiometer (about 5%) and BioMérieux (about 4%).
Further analysis of the current CVs and pass rates of main measurement systems for the two analytes are displayed on Tables 2 and
Percentages of laboratories meeting different allowable imprecision quality specifications for BNP and NTproBNP from 2014 to 2017 (Only NT-proBNP had allowable imprecision quality specification based on biological variation, including minimum, desirable, and optimum specification) (P = 0.026 and 0.002, respectively). Furthermore, analysis of the percentages of laboratories meeting quality requirements showed that pass rates of Roche increased significantly over the 4 years when using the 1/4TEa and desirable quality specifications (P = 0.002 and 0.001, respectively). Compared with the 1/3TEa and 1/4TEa criteria, the adoption of the stricter desirable and optimum specifications derived from biological variation could significantly decreased the pass rates of Roche (conducted by McNemar's test, all P < 0.001).
| Investigation of IQC practice
In this study, laboratories were required to submit control rules for BNP and NT-proBNP. We found that the constituent ratio of con- 
| D ISCUSS I ON
Under the circumstance of the high incidence of CVD, BNP and NTproBNP are very important biomarkers for the diagnosis of acute and chronic HF and for the assessment of prognosis. Therefore, the accuracy of their laboratory measurement is particularly important. CVs. 18 Based on results of this study, we recommended Roche for measurement system of NT-proBNP.
Actually, good IQC practice can effectively increase the error detection rate and reduce the rate of false rejection. 19, 20 In this study,
we evaluated the control rules and IQC frequency. We found that with great importance laboratories attaching to IQC and effective training provided by the NCCL, more and more laboratories gradually understand the concept of control rules and start using multiple control rules. At the same time, IQC frequency has also changed.
About 47% of laboratories performed IQC at intervals not exceeding 1 day, and the percentages of laboratories performing an IQC for more than 2 days also had a decrease. were still more than half of laboratories carrying out only one concentration level of control materials, indicating that more than half of laboratories failed to perform IQC as required. Besides, the measurement range of each level was also not specified, so there may be an overlap between two levels. 26 Thirdly, there is currently no allowable imprecision quality specifications based on biological variation for BNP currently. Quality specifications based on TEa, which are provided by evaluation criteria for EQA in laboratory medicine, are only at level 4 of the quality specifications hierarchy model, while the quality specifications based on biological variation are at level 2. The advantages of quality specifications based on biological variation are that it can be used in all laboratories according to medical requirements (regardless of the size, type, and location of the laboratory). It is widely accepted because it is simple to use and easy to understand. 27, 28 According to the results of our study, approximately 90% of laboratories can meet 1/4TEa, so it is recommended to use 1/4TEa as the criterion to evaluate the imprecision level of measurement of BNP. In the future, we need to include more laboratories and select different types of hospitals for further study. We should not only assess the imprecision level within a laboratory, but evaluate the inter-laboratory imprecision level as well. The NCCL is also supposed to organize more training programs about quality management, which could strengthen the awareness of quality management and improve the ability of clinical laboratory managers. We appeal to more laboratories in China to participate in the IQC programs.
In this study, we collected and analyzed the IQC data of BNP 
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